{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:06:10Z","timestamp":1778663170001,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":279,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>HIV\u20101 protease inhibitors often cause dyslipidemia, necessitating the use of lipid\u2010lowering agents such as rosuvastatin. However, when given concomitantly, these therapeutic agents often exhibit adverse drug interactions. In this study (phase I open\u2010label trial, n = 12 HIV\u20101 seronegative participants), the authors assessed the drug interactions between darunavir\/ritonavir given in combination with rosuvastatin. Participants were randomized to receive rosuvastatin (10 mg\/day) or darunavir\/ritonavir (600\/100 mg twice daily) alone for 7 days in a crossover design followed by combination therapy for 7 days with intervening 7\u2010day washout periods. Intensive blood sampling for pharmacokinetics and fasting lipids was performed on days 7, 21, and 35. The geometric mean AUC<jats:sub>0\u201324 h<\/jats:sub> of rosuvastatin increased from 109 to 161 ng\u00b7h\/mL (P &lt; .005) and C<jats:sub>max<\/jats:sub> increased 6.7 to 16.3 ng\/mL (P &lt; .001) when coadministered with darunavir\/ritonavir. In the presence of darunavir\/ritonavir and rosuvastatin, total cholesterol and triglyceride levels increased by 10% (P = .007) and 56% (P = .011), whereas the high\u2010density lipoprotein cholesterol levels decreased by 13% (P = .006) relative to rosuvastatin administration alone. There were no significant adverse events attributable to the coadministration of these drugs. Rosuvastatin levels increase in the presence of darunavir\/ritonavir coadministration, whereas the lipid\u2010lowering benefits are blunted. The clinical significance of these changes requires further investigation.<\/jats:p>","DOI":"10.1177\/0091270011407494","type":"journal-article","created":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T04:41:56Z","timestamp":1309322516000},"page":"922-931","source":"Crossref","is-referenced-by-count":31,"title":["Steady\u2010State Pharmacokinetic Interactions of Darunavir\/Ritonavir With Lipid\u2010Lowering Agent Rosuvastatin"],"prefix":"10.1002","volume":"52","author":[{"given":"Divya","family":"Samineni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj B.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Sallans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Fichtenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702009000500012"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2001.00063.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/382531"},{"key":"e_1_2_6_5_2","unstructured":"GatheJ daSilvaBA LoutfyM et al.Study M05\u2014730 primary efficacy results at week 48: phase 3 randomized open\u2010label study of lopinavir\/ritonavir (LPV\/r) tablets once daily (qd) versus twice daily (bid) co\u2010administered with tenofovir DF (TDF) + emtricit\u2010abine (FTC) in antiretroviral\u2010na\u00efve (ARV) HIV\u20101\u2013infected subjects. Poster presented at: 15th Conference on Retroviruses and Opportunistic Infections;2008; Boston MA."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0829"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006298603"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363080-00004"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544100-00003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832d7350"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/378131"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016089"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-005-5271-y"},{"key":"e_1_2_6_14_2","unstructured":"CarrRA AndreAK BertzRJ.Concomitant administration of ABT\u2010378\/ritonavir results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin. Poster presented at: 40th Conference on Antimicrobial Agents and Chemotherapy;2000; Toronto Ontario Canada."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00008"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318160a542"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.128469"},{"key":"e_1_2_6_18_2","unstructured":"SekarVJ Spinosa\u2010GuzmanS MarienK et al.Pharmacokinetic drug\u2010drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid\u2010lowering agent pravastatin. Poster presented at: Eighth International Workshop on Clinical Pharmacology of HIV Therapy;2007; Budapest Hungary."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00530-7"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2005.05.005"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.021410"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.02.034"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.03.010"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.09.011"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2009.10.009"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0508-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498250903509375"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.043026"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070112"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.005"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq209"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270011407494","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270011407494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:26:21Z","timestamp":1698639981000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270011407494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1177\/0091270011407494"],"URL":"https:\/\/doi.org\/10.1177\/0091270011407494","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}